

Amend CSSB 14 (house committee report) by striking page 3, line 27, through page 4, line 18, and substituting the following:

(b) Section 161.702 does not apply to the provision, prescription, administration, or dispensing of a prescription drug to a child that is otherwise prohibited by that section if:

(1) the child has been diagnosed with severe gender dysphoria by two physicians or health care providers with relevant training in the diagnosis and treatment of gender dysphoria in children and two mental health professionals or adolescent medicine specialists with relevant training in the diagnosis and treatment of gender dysphoria in children;

(2) each diagnosing physician, provider, professional, or specialist described by Subdivision (1) includes in the child's medical record a signed statement that the provision of the prescription drug is medically necessary to:

(A) treat the child's severe gender dysphoria;
and

(B) limit self harm or the possibility of self harm by the child;

(3) after being informed of the potential side effects of providing the prescription drug, the child, the child's parent or legal guardian, and the child's primary care physician each consent in writing to the provision of the prescription drug; and

(4) the prescription drug is provided, prescribed, administered, and dispensed at the lowest dose necessary to treat the child's severe gender dysphoria.

(c) The commission shall establish an impartial panel of physicians, health care providers, mental health professionals, and adolescent medicine specialists to evaluate the legitimacy and severity of a gender dysphoria diagnosis under Subsection (b)(1).